Clinical trial
AN INTERVENTIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF ATIRMOCICLIB (PF-07220060) PLUS GIREDESTRANT COMPARED TO GIREDESTRANT MONOTHERAPY AS ADJUVANT TREATMENT IN ADULT PARTICIPANTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE EARLY-STAGE BREAST CANCER WITH MEDIUM OR HIGH RISK OF RECURRENCE (FOURLIGHT-4)
NCT07890597 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- AN INTERVENTIONAL, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF ATIRMOCICLIB (PF-07220060) PLUS GIREDESTRANT COMPARED TO GIREDESTRANT MONOTHERAPY AS ADJUVANT TREATMENT IN ADULT PARTICIPANTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE EARLY-STAGE BREAST CANCER WITH MEDIUM OR HIGH RISK OF RECURRENCE (FOURLIGHT-4)
- Lead sponsor
- Pfizer
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- August 20, 2042
- Enrollment
- 3,800 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
early breast cancer, estrogen receptor positive (er+), human epidermal growth factor receptor 2 negative (her2-)
Lead sponsor's other trials
Pfizer, most recent start first.
+3,329 more trials See the organization page
Similar trials
Same condition (Breast Neoplasms) and phase, most recent start first.
+1,149 more trials See the condition page